Andrew L Laccetti

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 3

Top Topics

Combination Therapy

Tyrosine Kinase

Metastatic Renal Cell Carcinoma

Chronic Myeloid Leukemia

Top Venues

OncoTargets and therapy

Clinical nuclear medicine

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew L Laccetti, Lisa Bodei, Joseph A O'Donoghue, Wolfgang A Weber, Michael J Morris
A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Clinical nuclear medicine 48 (11) (2023)
Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas P Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer medicine 10 (7) (2021)
Andrew L Laccetti, Michael J Morris, Philip W Kantoff
A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. OncoTargets and therapy 13 (2020)